Bio-Connect

c-Met antibody [C3], C-term

GTX100637
GeneTex
ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry
Product group Antibodies
TargetMET
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    c-Met antibody [C3], C-term
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IP: 1:100-1:500. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1.95 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID4233
  • Target name
    MET
  • Target description
    MET proto-oncogene, receptor tyrosine kinase
  • Target synonyms
    AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met, hepatocyte growth factor receptor, HGF receptor, HGF/SF receptor, SF receptor, proto-oncogene c-Met, scatter factor receptor, tyrosine-protein kinase Met
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDP08581
  • Protein Name
    Hepatocyte growth factor receptor
  • Scientific Description
    The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq]
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • De Tomi E, Campagnari R, Orlandi E, et al. Upregulation of miR-34a-5p, miR-20a-3p and miR-29a-3p by Onconase in A375 Melanoma Cells Correlates with the Downregulation of Specific Onco-Proteins. Int J Mol Sci. 2022,23(3). doi: 10.3390/ijms23031647
    Read this paper
  • Pang HH , Huang CY , Chou YW , et al. Bioengineering fluorescent virus-like particle/RNAi nanocomplexes act synergistically with temozolomide to eradicate brain tumors. Nanoscale. 2019,11(17):8102-8109. doi: 10.1039/c9nr01247h
    Read this paper
  • Chen ST, Kuo TC, Liao YY, et al. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Oncogene. 2018,37(46):6041-6053. doi: 10.1038/s41388-018-0403-0
    Read this paper
  • Pei YF, Yin XM, Liu XQ. TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2018,1864(1):197-207. doi: 10.1016/j.bbadis.2017.10.019
    Read this paper
  • Wang C, Tseng T, Jhang Y, et al. Loss of cell invasiveness through PKC-mediated syndecan-1 downregulation in melanoma cells under anchorage independency. Exp Dermatol. 2014,23(11):843-9. doi: 10.1111/exd.12550
    Read this paper
  • Wu YM, Liu CH, Huang MJ, et al. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Cancer Res. 2013,73(17):5580-90. doi: 10.1158/0008-5472.CAN-13-0869
    Read this paper
  • Lin WC, Tsai HF, Kuo SH, et al. Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res. 2010,70(14):5740-8. doi: 10.1158/0008-5472.CAN-09-4690
    Read this paper